MELK has been considered a potential target for cancer therapy because of the interaction with multiple proteins at distinct stages of tumorigenesis [29, 30], and the first MELK-specific small molecular compound, OTSSP167, was developed [29]. The gene discussed is MELK; the disease is cancer.